Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy

Diabetes Technology and Therapeutics

Volumn 15, Issue 3, 2013, Pages 237-240

  Mori, Yutaka ^a,b   Taniguchi, Yukiko ^c   Miyazaki, Shigeru ^c   Yokoyama, Junichi ^a   Utsunomiya, Kazunori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kawachi gun   (Japan)

^c Department of Surgery   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; SITAGLIPTIN;

ADD ON THERAPY; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; INSULIN TREATMENT; JAPANESE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PILOT PROJECTS; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; PYRAZINES; TRIAZOLES;

EID: 84875146474     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0214     Document Type: Article

References (6)

1. The DECODE Study Group: Glucose tolerance and mortality: Comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999;354:617-621
2. The STOP-NIDDM Trial Research Group: Acarbose for prevention of type 2 diabetes mellitus: The STOPNIDDM randomized trial. Lancet 2002;359:2072-2077
3. Drucker DJ, Nauck MA: The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705 (Pubitemid 46048557)
4. Mori Y, Taniguchi Y, Matsuura K, Sezaki K, Yokoyama J, Utsunomiya K: Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring. Diabetes Technol Ther 2011; 13:699-703
5. Hong ES, Khang AR, Yoon JW, Kang SM, Choi SH, Park KS, Jang HC, Shin H, Walford GA, Lim S: Comparison between sitagliptin as add-on therapy to insulin and insulin doseincrease therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes 2012;14:795-802
6. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur Heart J 2004:25:10-16 (Pubitemid 38055587)